Skip to main content

Advertisement

SpringerLink
Log in

Systematic review of severe acute liver injury caused by terbinafine

  • Review Article
  • Published:
International Journal of Clinical Pharmacy Aims and scope Submit manuscript

Abstract

Background Terbinafine is an effective antimicrobial agent against dermatophytes, cryptococcus and other fungi. It is the preferred drug to treat onychomycosis. However, severe acute hepatitis from oral terbinafine administration has been recently reported. Aim To describe a representative case, and review the literature regarding the best evidence on treatment and prognosis of severe acute hepatitis caused by oral terbinafine. Methods The literature was searched for publications on severe hepatitis caused by terbinafine using MEDLINE, China Biology Medicine Disc, and the VIP Medical Information Resource System. Related references were searched manually. Results Seventeen English and three Chinese references of case reports were included after eliminating duplicate publications. No randomized control studies were found. Liver enzyme levels were found to have been increased significantly. Abdominal ultrasound demonstrated cholestasis. Conclusions Severe acute liver injury is a known, but unusual complication of terbinafine exposure. The prognosis is often good with appropriate treatment. Liver function assessment before treatment and periodic monitoring 4–6 weeks after initiation of treatment is recommended.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Hay RJ. Risk/benefit ratio of modern antifungal therapy: focus on hepatic reactions. J Am Acad Dermatol. 1993;29:S50–4.

    Article  CAS  PubMed  Google Scholar 

  2. Gupta AK, del Rosso JQ, Lynde CW, Brown GH, Shear NH. Hepatitis associated with terbinafine therapy: three case reports and a review of the literature. Clin Exp Dermatol. 1998;23:64–7.

    Article  CAS  PubMed  Google Scholar 

  3. Itraconazole, terbinafine possibly linked to liver failure. Am J Health Syst Pharm. 2001; 58: 1076.

  4. Hepatic reactions with terbinafine. Aust Adverse Drug React Bull. 2008;27:2.

  5. Xiao Z, Yanqing LI. Japan revised terbinafinewarning. Chin Pharmacist. 2004;7:479.

    Google Scholar 

  6. Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ. 2009;339:b2535.

    Article  PubMed Central  PubMed  Google Scholar 

  7. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials. 1996;17:1–12.

    Article  CAS  PubMed  Google Scholar 

  8. Lowe G, Green C, Jennings P. Hepatitis associated with terbinafine treatment. BMJ. 1993;306:248.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  9. van ‘t Wout JW, Herrmann WA, De Vries RA, Stricker BH. Terbinafine-associated hepatic injury. J Hepatol. 1994;21:115–7.

    Article  Google Scholar 

  10. Lazaros GA, Papatheodoridis GV, Delladetsima JK, Tassopoulos NC. Terbinafine-induced cholestatic liver disease. J Hepatol. 1996;24:753–6.

    Article  CAS  PubMed  Google Scholar 

  11. Dwyer CM, White MI, Sinclair TS. Cholestatic jaundice due to terbinafine. Br J Dermatol. 1997;136:976–7.

    Article  CAS  PubMed  Google Scholar 

  12. Mallat A, Zafrani ES, Metreau JM, Dhumeaux D. Terbinafine-induced prolonged cholestasis with reduction of interlobular bile ducts. Dig Dis Sci. 1997;42:1486–8.

    Article  CAS  PubMed  Google Scholar 

  13. Fernandes NF, Geller SA, Fong TL. Terbinafine hepatotoxicity: case report and review of the literature. Am J Gastroenterol. 1998;93:459–60.

    Article  CAS  PubMed  Google Scholar 

  14. Gupta AK, Porges AJ. Hypersensitivity syndrome reaction to oral terbinafine. Australas J Dermatol. 1998;39(3):171–2.

    Article  CAS  PubMed  Google Scholar 

  15. Agarwal K, Manas DM, Hudson M. Terbinafine and fulminant hepatic failure. N Engl J Med. 1999;340:1292–3.

    Article  CAS  PubMed  Google Scholar 

  16. Conjeevaram G, Vongthavaravat V, Sumner R, Koff RS. Terbinafine-induced hepatitis and pancytopenia. Dig Dis Sci. 2001;46:1714–6.

    Article  CAS  PubMed  Google Scholar 

  17. Chambers WM, Millar A, Jain S, Burroughs AK. Terbinafine-induced hepatic dysfunction. Eur J Gastroenterol Hepatol. 2001;13:1115–8.

    Article  CAS  PubMed  Google Scholar 

  18. Ajit C, Suvannasankha A, Zaeri N, Munoz SJ. Terbinafine-associated hepatotoxicity. Am J Med Sci. 2003;32:292–5.

    Article  Google Scholar 

  19. Agca E, Akcay A, Simsek H. Ursodeoxycholic acid for terbinafine-induced toxic hepatitis. Ann Pharmacother. 2004;38:1088–9.

    Article  PubMed  Google Scholar 

  20. Xin S. Terbinafine hydrochloride caused by drug hepatic damage. Clin Med Chin. 2004;20:515.

    Google Scholar 

  21. Xiaoqin LV, Zhang X. Terbinafine cause cholestasis hepatitis one case. Herald Med. 2006;25:593.

    Google Scholar 

  22. Perveze Z, Johnson MW, Rubin RA, Sellers M, Zayas C, Jones JL, et al. Terbinafine-induced hepatic failure requiring liver transplantation. Liver Transpl. 2007;13:162–4.

    Article  PubMed  Google Scholar 

  23. Kim BS, Jang HS, Jwa SW, Jang BS, Kim MB, Oh CK, et al. Generalized pustular psoriasis and hepatic dysfunction associated with oral terbinafine therapy. J Korean Med Sci. 2007;22:167–9.

    Article  PubMed Central  PubMed  Google Scholar 

  24. Paredes AH, Lewis JH. Terbinafine-induced acute autoimmune hepatitis in the setting of hepatitis B virus infection. Ann Pharmacother. 2007;41:880–4.

    Article  CAS  PubMed  Google Scholar 

  25. Gendre G, Buclin T, Morard I, Fontannaz J, Berney JL. Terbinafine induced hepatitis with persistent cholestasis. Rev Med Suisse. 2008;4:736–9.

    CAS  PubMed  Google Scholar 

  26. Jing B, Yang Y. Terbinafine cause cholestasis hepatitis. ADRJ. 2008;10:284.

    Google Scholar 

  27. Tausch I, Bräutigam M, Weidinger G, Jones TC. Evaluation of 6 weeks treatment of terbinafine in tinea unguium in a double-blind trial comparing 6 and 12 weeks therapy. The Lagos V Study Group. Br J Dermatol. 1997;136(5):737–42.

    Article  CAS  PubMed  Google Scholar 

  28. Gupta AK, Lynde CW, Konnikov N. Single-blind, randomized, prospective study of sequential itraconazole and terbinafine pulse compared with terbinafine pulse for the treatment of toenail onychomycosis. J Am Acad Dermatol. 2001;44(3):485–91.

    Article  CAS  PubMed  Google Scholar 

  29. Baran R, Feuilhade M, Combernale P, Datry A, Goettmann S, Pietrini P, et al. A randomized trial of amorolfine 5% solution nail lacquer combined with oral terbinafine compared with terbinafine alone in the treatment of dermatophytic toenail onychomycoses affecting the matrix region. Br J Dermatol. 2000;142(6):1177–83.

    Article  CAS  PubMed  Google Scholar 

  30. De Backer M, De Vroey C, Lesaffre E, Scheys I, De Keyser P. Twelve weeks of continuous oral therapy for toenail onychomycosis caused by dermatophytes: a double-blind comparative trial of terbinafine 250 mg/day versus itraconazole 200 mg/day. J Am Acad Dermatol. 1998;38(5 Pt 3):S57–63.

    Article  PubMed  Google Scholar 

  31. Chang CH, Young-Xu Y, Kurth T, Orav JE, Chan AK. The safety of oral antifungal treatments for superficial dermatophytosis and onychomycosis: a meta-analysis. Am J Med. 2007;120:791–8.

    Article  CAS  PubMed  Google Scholar 

  32. Gupta AK, Ryder JE, Johnson AM. Cumulative meta-analysis of systemic antifungal agents for the treatment of onychomycosis. Br J Dermatol. 2004;150:537–44.

    Article  CAS  PubMed  Google Scholar 

  33. Krob AH, Fleischer AB Jr, D’Agostino R Jr, Feldman SR. Terbinafine is more effective than itraconazole in treating toenail onychomycosis: results from a meta-analysis of randomized controlled trials. J Cutan Med Surg. 2003;7:306–11.

    Article  PubMed  Google Scholar 

  34. Casciano J, Amaya K, Doyle J, Arikian S, Shear N, Haspel M, Kahler K. Economic analysis of oral and topical therapies for onychomycosis of the toenails and fingernails. Manag Care. 2003;12:47–54.

    PubMed  Google Scholar 

  35. Haugh M, Helou S, Boissel JP, Cribier BJ. Terbinafine in fungal infections of the nails: a meta-analysis of randomized clinical trials. Br J Dermatol. 2002;147:118–21.

    Article  CAS  PubMed  Google Scholar 

  36. Gupta AK. Treatment of dermatophyte toenail onychomycosis in the United States. A pharmacoeconomic analysis. J Am Podiatr Med Assoc. 2002;92:272–86.

    Article  PubMed  Google Scholar 

  37. Gupta AK, Lambert J. Pharmacoeconomic analysis of the new oral antifungal agents used to treat toenail onychomycosis in the USA. Int J Dermatol. 1999;38:S53–64.

    Article  Google Scholar 

  38. De Doncker P. Itraconazole and terbinafine in perspective: from petri dish to patient. J Eur Acad Dermatol Venereol. 1999;12:S10–6.

    PubMed  Google Scholar 

  39. Marchetti A, Piech CT, McGhan WF, Neugut AI, Smith BT. Pharmacoeconomic analysis of oral therapies for onychomycosis: a US model. Clin Ther. 1996;18:757–77.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

Lei CUI, Xiaodan LV: Jinan Infectious Disease Hospital, Liver Disease Diagnosis and Treatment Center of Shandong Province, Jinan, 250013 China.

Funding

No funding was received to support this work.

Conflicts of interest

The authors have no conflicts of interest.

Author information

Authors and Affiliations

  1. Jinan City Hospital for Skin Diseases Prevention and Treatment, Jinan, 250001, China

    Jun Yan & Xiaolin Wang

  2. Shandong Provincial Institute of Dermatology and Venereology, Shandong Acdemy of Medical Sciences, Jinan, 250022, China

    Shengli Chen

Authors
  1. Jun Yan
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Xiaolin Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Shengli Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Shengli Chen.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Yan, J., Wang, X. & Chen, S. Systematic review of severe acute liver injury caused by terbinafine. Int J Clin Pharm 36, 679–683 (2014). https://doi.org/10.1007/s11096-014-9969-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11096-014-9969-y

Keywords

Search

Navigation